Sugi Predict
/ Targets
/ H1-2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to H1-2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients |
PHASE3 | UNKNOWN |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG |
PHASE1/PHASE2 | RECRUITING |
| Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | UNKNOWN |
| An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab |
PHASE1/PHASE2 | RECRUITING |
| An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma |
PHASE2 | COMPLETED |
| IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma |
PHASE1/PHASE2 | COMPLETED |
| A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas |
PHASE2 | WITHDRAWN |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia |
PHASE2 | UNKNOWN |
| Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma |
PHASE2 | RECRUITING |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes |
PHASE1 | COMPLETED |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma |
PHASE1 | UNKNOWN |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease |
PHASE1 | NOT_YET_RECRUITING |
| Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Intravenously Administered M6229 in Critically Ill Sepsis Patients |
PHASE1 | COMPLETED |
| Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins |
nan | COMPLETED |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia |
nan | COMPLETED |
| The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity |
nan | COMPLETED |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a H1-2 binder may also engage these)